Expert Q&As
First interactions with EMA - Q&A 5
How should we approach pricing
and reimbursement across EU countries?
Access decades of experience
What’s Inside the Q&A:
Country-Specific Value Strategies
Why a one-size-fits-all approach fails in Europe. How to tailor messaging to each market's unique assessment criteria.
Strategic Launch Sequencing
How reference pricing spillover effects impact revenue. The critical importance of launch order planning to avoid pricing pitfalls.
Flexible Pricing Models
Negotiation tactics including outcome-based agreements and risk-sharing models. How these facilitate payer acceptance for expensive therapies.
Early Market Access Planning
When to begin crafting reimbursement strategy and essential payer engagement timelines.
Download our Expert Q&A
Discover our latest news
Expert Q&As
First interactions with EMA - Q&A 1
What are the different regulatory pathways available when expanding to Europe and which one is the best fit for me?
Expert Q&As
First interactions with EMA - Q&A 2
How does the EU drug development landscape differ from the US ?
Expert Q&As
First interactions with EMA - Q&A 7
What regulatory pathway missteps should we avoid, and how can we streamline our EU dossier preparation?
